I’m honored to introduce this month’s newsletter. As head of Innovation & Strategic Accounts, I’m fortunate to be involved in some of our most recent initiatives.
In this Newsletter, you will find out what bats, NFTs and the British Royal family have to do with healthcare market research. See me also in a new episode of our DoctoLIVE series: these are designed as informative coffee breaks where you’ll hear a physician discussing both the challenges and exciting new areas in various diseases. And discover new exclusive content based on our recent syndicated research conducted in Hemophilia and how Social Media Intelligence can reveal trending discussions that directly impact Atopic Dermatitis management.
As a British-American binational, I’m grateful to be part of a global team across Europe and the US. At APLUSA we believe that success, innovation, and client satisfaction are a team effort and joint responsibility where we each play our own unique and important role.
Have fun, stay safe and enjoy life!
Karen Higginbottom, PhD.
US Head of Innovation and Strategic Accounts
What’s Trending these Last Months?
🎓 AplusACADEMY | Getting real with patient archetypes 🎓
Find out what bats, NFTs and the British Royal family have to do with healthcare market research in a fun and informative presentation that Steve Bell and Karen Higginbottom gave about our exclusive new approach to segmentation. You can watch the video and get even more real with our companion document providing a more technical exposition of our presentation titled: Evolving Beyond Patient Personas: Getting Real with Patient Archetypes.
Do you want to know more? Click the button below to get access to the video and an extra document!
This document will help you delve deeper in the technical aspects of getting real with patient archetypes. You will find here an actual example taken from a real-world patient chart study including 734 dementia patients:
Discover how to identify patient archetypes,
Compare to other methods applied, like the more traditional persona approach,
Discover optimal algorithms,
Read experiences and applications from real-world data.
🗣 DoctoLIVE mRCC episodes 1 & 2 Replays Available 🗣
SERIES 3: Challenges in implementing new therapeutics in mRCC management
In this mRCC DoctoLIVE series, we were questioning what are challenges in implementing new therapeutics in metastatic renal cell carcinoma in 2022. Click the buttons below to get access to our previous DoctoLIVEs sessions.
APLUSA Bell Falla at PMRC USA | MAY 10-11, 2022, NEWARK, NJ
Do You Believe What I Do Or What I Say? The Relentless Pursuit Of Accurate Demand Forecasts presented by APLUSA Bell Falla and EMD Serono.
Description: We’ve all heard the old saying that the only thing we know for certain about forecasts is that they’re wrong. There is a grain of truth in that observation. As market researchers and forecasters, a large part of our job is to understand the vagaries of the future market and find ways to bring more precision to estimating future share. The two main approaches to share estimation – global patient allocations, where we ask physicians for stated prescribing intent, and patient treatment scenarios, where we derive share from observing prescribing behavior – both have their advantages and disadvantages. In this session, we review results from several recent demand studies in which both methods were employed and discuss the benefits and drawbacks of each. We will highlight a significant problem but often hidden challenge we uncovered with global allocations. Finally, we will outline concrete recommendations for improving the dependability of your demand studies.
Atopic Dermatitis: are topical steroid-based treatments on the out?
Bringing attention to topical steroid withdrawal AKA #TSW
A social media listening study can be full of surprises, things you simply might not have anticipated. You set up your query, you have all the keywords ready, and a broad idea of the content you will find. Then you dig up something that goes beyond your expectations, a little nugget that just draws your attention, and of course, as a researcher, you just cannot help yourself and start digging deeper to see if there is something more to investigate there.
Interested in more of our other syndicated studies? Click here!
From 17 to 22 april 2022 took place the World Hemophilia Week, and to raise awareness, we shared on social media, 4 exclusive insights from our new wave conducted for hemophilia syndicated study.
INSIGHT 1
62% of Hemophilia A patients currently on long term prophylaxis across EU5 were directly treated with primary prophylaxis. Key reasons for choosing prophylaxis from the start included better joint protection and the severity of hemophilia.
38% switched from on-demand to prophylaxis. This proportion varied substantially by EU5 country from 22% to 52%.
INSIGHT 2
25% of Hemophilia A patients and 39% of Hemophilia B patients are treated with extended half-life products.
Patient request has a notable impact on product switching, being mentioned as one of the main reasons of 42% of HA treatment switches from non-HEL to EHL products, and 39% in HB.
INSIGHT 3
IA high number of Hemophilia A & B patients on prophylaxis treatments are continuing to experience bleed events, pointing to significant unmet needs in quality of life and cost of disease management.
62% of HA and 59% of HB patients on prophylaxis had at least 1 bleed in the past 12 months requiring on-demand injections.
INSIGHT 4
About one in four HA patients in the EU5 have ever had factor VIII inhibitors: 27%.
About one in five HB patients in the EU5 have ever had factor IX inhibitors: 19%.
Of these inhibitor patients, 60% in HA and 69% HB have received immune tolerance induction (ITI) therapy.
Don't forget these coming weeks, these world/international health days to spread awareness, or add to your agenda:
WORLD ASTHMA DAY
INTERNATIONAL NURSES DAY
WORLD BRAIN TUMOR DAY
WORLD BLOOD DONOR DAY
Tuesday, 3rd of May
Thursday, 12th of May
Wednesday, 8th of June
Tuesday, 14th of June
About the Teams
🎬 Fast & Curious #3 by APLUSALife 🎬
APLUSA or A+A? OL or PSG? Pain au chocolat or Chocolatine??? Meet six of our collaborators in this third Fast&Curious interview 100% Parisian 🗼 (or almost 😉)!
🎉 APLUS7 in March and April! 🎉
These past months, we were very excited to warmly welcome our seven new collaborators within our Lyon and Paris offices! Welcome to the team Michel, Noémia, Victor, Gaëlle, Shahryar, Zoé and Florian! 🎉
